Oxidative Stress and Cardiac Muscle

Muscle: Fundamental Biology and Mechanisms of Disease

Volumn 1-2, Issue , 2012, Pages 309-322

  Maejima, Yasuhiro ^a   Zablocki, Daniela ^a   Sadoshima, Junichi ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882906821     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-381510-1.00023-5     Document Type: Chapter

References (139)

1. Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005, 115:500-508.
2. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003, 15:247-254.
3. Lambeth J.D. Nox enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004, 4:181-189.
4. Bedard K., Krause K.H. The Nox family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87:245-313.
5. Babior B.M., Kipnes R.S., Curnutte J.T. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest 1973, 52:741-744.
6. Gorlach A., Brandes R.P., Nguyen K., Amidi M., Dehghani F., Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000, 87:26-32.
7. Pagano P.J., Clark J.K., Cifuentes-Pagano M.E., Clark S.M., Callis G.M., Quinn M.T. Localization of a constitutively active, phagocyte-like NADPH oxidase in rabbit aortic adventitia: enhancement by angiotensin II. Proc Natl Acad Sci USA 1997, 94:14483-14488.
8. Ushio-Fukai M., Tang Y., Fukai T., Dikalov S.I., Ma Y., Fujimoto M., et al. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res 2002, 91:1160-1167.
9. Heymes C., Bendall J.K., Ratajczak P., Cave A.C., Samuel J.L., Hasenfuss G., et al. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003, 41:2164-2171.
10. Ago T., Kuroda J., Pain J., Fu C., Li H., Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 2010, 106:1253-1264.
11. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 2008, 275:3249-3277.
12. Lambeth J.D., Kawahara T., Diebold B. Regulation of Nox and duox enzymatic activity and expression. Free Radic Biol Med 2007, 43:319-331.
13. Abo A., Pick E., Hall A., Totty N., Teahan C.G., Segal A.W. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 1991, 353:668-670.
14. Uhlinger D.J., Taylor K.L., Lambeth J.D. P67-phox enhances the binding of p47-phox to the human neutrophil respiratory burst oxidase complex. J Biol Chem 1994, 269:22095-22098.
15. Ago T., Kuribayashi F., Hiroaki H., Takeya R., Ito T., Kohda D., et al. Phosphorylation of p47phox directs phox homology domain from SH3 domain toward phosphoinositides, leading to phagocyte NADPH oxidase activation. Proc Natl Acad Sci USA 2003, 100:4474-4479.
16. Quinn M.T., Evans T., Loetterle L.R., Jesaitis A.J., Bokoch G.M. Translocation of Rac correlates with NADPH oxidase activation. Evidence for equimolar translocation of oxidase components. J Biol Chem 1993, 268:20983-20987.
17. Ambasta R.K., Kumar P., Griendling K.K., Schmidt H.H., Busse R., Brandes R.P. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 2004, 279:45935-45941.
18. Geiszt M., Kopp J.B., Varnai P., Leto T.L. Identification of Renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 2000, 97:8010-8014.
19. Shiose A., Kuroda J., Tsuruya K., Hirai M., Hirakata H., Naito S., et al. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 2001, 276:1417-1423.
20. Lyle A.N., Deshpande N.N., Taniyama Y., Seidel-Rogol B., Pounkova L., Du P., et al. Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. Circ Res 2009, 105:249-259.
21. Bolwell G.P., Butt V.S., Davies D.R., Zimmerlin A. The origin of the oxidative burst in plants. Free Radic Res 1995, 23:517-532.
22. George J., Struthers A.D. The role of urate and xanthine oxidase inhibitors in cardiovascular disease. Cardiovasc Ther 2008, 26:59-64.
23. Bergamini C., Cicoira M., Rossi A., Vassanelli C. Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail 2009, 11:444-452.
24. Kim J.W., Baek B.S., Kim Y.K., Herlihy J.T., Ikeno Y., Yu B.P., et al. Gene expression of cyclooxygenase in the aging heart. J Gerontol A Biol Sci Med Sci 2001, 56:B350-B355.
25. Landmesser U., Dikalov S., Price S.R., McCann L., Fukai T., Holland S.M., et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003, 111:1201-1209.
26. Tsutsui H., Kinugawa S., Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 2009, 81:449-456.
27. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., et al. Mitochondrial electron transport complex i is a potential source of oxygen free radicals in the failing myocardium. Circ Res 1999, 85:357-363.
28. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
29. Kuroda J., Ago T., Matsushima S., Zhai P., Schneider M.D., Sadoshima J. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 2010, 107:15565-15570.
30. Santos C.X., Tanaka L.Y., Wosniak J., Laurindo F.R. Mechanisms and implications of reactive oxygen species generation during the unfolded protein response: roles of endoplasmic reticulum oxidoreductases, mitochondrial electron transport, and NADPH oxidase. Antioxid Redox Signal 2009, 11:2409-2427.
31. Vogt W. Oxidation of methionyl residues in proteins: tools, targets, and reversal. Free Radic Biol Med 1995, 18:93-105.
32. Brot N., Weissbach L., Werth J., Weissbach H. Enzymatic reduction of protein-bound methionine sulfoxide. Proc Natl Acad Sci USA 1981, 78:2155-2158.
33. Rahman M.A., Nelson H., Weissbach H., Brot N. Cloning, sequencing, and expression of the Escherichia coli peptide methionine sulfoxide reductase gene. J Biol Chem 1992, 267:15549-15551.
34. Moskovitz J., Weissbach H., Brot N. Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins. Proc Natl Acad Sci USA 1996, 93:2095-2099.
35. Hoshi T., Heinemann S. Regulation of cell function by methionine oxidation and reduction. J Physiol 2001, 531:1-11.
36. Nan C., Li Y., Jean-Charles P.Y., Chen G., Kreymerman A., Prentice H., et al. Deficiency of methionine sulfoxide reductase a causes cellular dysfunction and mitochondrial damage in cardiac myocytes under physical and oxidative stresses. Biochem Biophys Res Commun 2010, 402:608-613.
37. Erickson J.R., Joiner M.L., Guan X., Kutschke W., Yang J., Oddis C.V., et al. A dynamic pathway for calcium-independent activation of CAMKII by methionine oxidation. Cell 2008, 133:462-474.
38. Gladyshev V.N. Thioredoxin and peptide methionine sulfoxide reductase: convergence of similar structure and function in distinct structural folds. Proteins 2002, 46:149-152.
39. Xu D. Rovira, II, Finkel T. Oxidants painting the cysteine chapel: redox regulation of PTPs. Dev Cell 2002, 2:251-252.
40. Tabet F., Schiffrin E.L., Callera G.E., He Y., Yao G., Ostman A., et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res 2008, 103:149-158.
41. Barford D. The role of cysteine residues as redox-sensitive regulatory switches. Curr Opin Struct Biol 2004, 14:679-686.
42. Mitsushita J., Lambeth J.D., Kamata T. The superoxide-generating oxidase Nox1 is functionally required for Ras oncogene transformation. Cancer Res 2004, 64:3580-3585.
43. Ago T., Liu T., Zhai P., Chen W., Li H., Molkentin J.D., et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008, 133:978-993.
44. Han M.J., Kim B.Y., Yoon S.O., Chung A.S. Cell proliferation induced by reactive oxygen species is mediated via mitogen-activated protein kinase in Chinese hamster lung fibroblast (v79) cells. Mol Cells 2003, 15:94-101.
45. Mehdi M.Z., Pandey N.R., Pandey S.K., Srivastava A.K. H2O2-induced phosphorylation of ERK1/2 and PKB requires tyrosine kinase activity of insulin receptor and c-Src. Antioxid Redox Signal 2005, 7:1014-1020.
46. Ushio-Fukai M. Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc Res 2006, 71:226-235.
47. Griendling K.K., Sorescu D., Lassegue B., Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000, 20:2175-2183.
48. Touyz R.M., Yao G., Viel E., Amiri F., Schiffrin E.L. Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells. J Hypertens 2004, 22:1141-1149.
49. Sanchez G., Pedrozo Z., Domenech R.J., Hidalgo C., Donoso P. Tachycardia increases NADPH oxidase activity and RyR2 S-glutathionylation in ventricular muscle. J Mol Cell Cardiol 2005, 39:982-991.
50. Cherednichenko G., Zima A.V., Feng W., Schaefer S., Blatter L.A., Pessah I.N. NADH oxidase activity of rat cardiac sarcoplasmic reticulum regulates calcium-induced calcium release. Circ Res 2004, 94:478-486.
51. Zeng Q., Zhou Q., Yao F., O'Rourke S.T., Sun C. Endothelin-1 regulates cardiac l-type calcium channels via NAD(P)H oxidase-derived superoxide. J Pharmacol Exp Ther 2008, 326:732-738.
52. Zhou C., Ziegler C. Birder LA, Stewart AF, Levitan ES. Angiotensin II and stretch activate NADPH oxidase to destabilize cardiac KV4.3 channel mRNA. Circ Res 2006, 98:1040-1047.
53. Ren Z., Raucci F.J., Browe D.M., Baumgarten C.M. Regulation of swelling-activated cl(?) current by angiotensin II signalling and NADPH oxidase in rabbit ventricle. Cardiovasc Res 2008, 77:73-80.
54. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82:47-95.
55. Irani K. Oxidant signaling in vascular cell growth, death, and survival : a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000, 87:179-183.
56. Ushio-Fukai M., Alexander R.W. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 2004, 264:85-97.
57. Woo H.A., Yim S.H., Shin D.H., Kang D., Yu D.Y., Rhee S.G. Inactivation of peroxiredoxin I by phosphorylation allows localized H(2)O(2) accumulation for cell signaling. Cell 2010, 140:517-528.
58. Li J.M., Shah A.M. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002, 277:19952-19960.
59. Petry A., Djordjevic T., Weitnauer M., Kietzmann T., Hess J., Gorlach A. Nox2 and Nox4 mediate proliferative response in endothelial cells. Antioxid Redox Signal 2006, 8:1473-1484.
60. Van Buul J.D., Fernandez-Borja M., Anthony E.C., Hordijk P.L. Expression and localization of Nox2 and Nox4 in primary human endothelial cells. Antioxid Redox Signal 2005, 7:308-317.
61. Zhang M., Brewer A.C., Schroder K., Santos C.X., Grieve D.J., Wang M., et al. NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 2010, 107:18121-18126.
62. Buggisch M., Ateghang B., Ruhe C., Strobel C., Lange S., Wartenberg M., et al. Stimulation of ES-cell-derived cardiomyogenesis and neonatal cardiac cell proliferation by reactive oxygen species and NADPH oxidase. J Cell Sci 2007, 120:885-894.
63. Schmelter M., Ateghang B., Helmig S., Wartenberg M., Sauer H. Embryonic stem cells utilize reactive oxygen species as transducers of mechanical strain-induced cardiovascular differentiation. FASEB J 2006, 20:1182-1184.
64. Doerries C., Grote K., Hilfiker-Kleiner D., Luchtefeld M., Schaefer A., Holland S.M., et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ Res 2007, 100:894-903.
65. Li J., Stouffs M., Serrander L., Banfi B., Bettiol E., Charnay Y., et al. The NADPH oxidase Nox4 drives cardiac differentiation: role in regulating cardiac transcription factors and map kinase activation. Mol Biol Cell 2006, 17:3978-3988.
66. 2+ channel. Mol Pharmacol 1998, 53:497-503.
67. Rowe G.T., Manson N.H., Caplan M., Hess M.L. Hydrogen peroxide and hydroxyl radical mediation of activated leukocyte depression of cardiac sarcoplasmic reticulum. Participation of the cyclooxygenase pathway. Circ Res 1983, 53:584-591.
68. Zima A.V., Blatter L.A. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006, 71:310-321.
69. Acker H. Mechanisms and meaning of cellular oxygen sensing in the organism. Respir Physiol 1994, 95:1-10.
70. Brandle M., Wang W., Zucker I.H. Ventricular mechanoreflex and chemoreflex alterations in chronic heart failure. Circ Res 1994, 74:262-270.
71. Ponikowski P., Chua T.P., Piepoli M., Ondusova D., Webb-Peploe K., Harrington D., et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 1997, 96:2586-2594.
72. Wang G.L., Jiang B.H., Rue E.A., Semenza G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995, 92:5510-5514.
73. Lee Y., Kim B., Chun Y., So I., Choi H., Kim M., et al. Nox4 as an oxygen sensor to regulate task-1 activity. Cell Signal 2006, 18:499-507.
74. Ventura-Clapier R., Garnier A., Veksler V. Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc Res 2008, 79:208-217.
75. Halestrap A.P., Clarke S.J., Javadov S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res 2004, 61:372-385.
76. Dai D.F., Santana L.F., Vermulst M., Tomazela D.M., Emond M.J., MacCoss M.J., et al. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 2009, 119:2789-2797.
77. Goffart S., von Kleist-Retzow J.C., Wiesner R.J. Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res 2004, 64:198-207.
78. Fu C., Wu C., Liu T., Ago T., Zhai P., Sadoshima J., et al. Elucidation of thioredoxin target protein networks in mouse. Mol Cell Proteomics 2009, 8:1674-1687.
79. Ide T., Tsutsui H., Hayashidani S., Kang D., Suematsu N., Nakamura K., et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001, 88:529-535.
80. Dai D.F., Rabinovitch P.S. Cardiac aging in mice and humans: the role of mitochondrial oxidative stress. Trends Cardiovasc Med 2009, 19:213-220.
81. Tsutsui H., Kinugawa S., Matsushima S. Oxidative stress and mitochondrial DNA damage in heart failure. Circ J. 2008, 72(Suppl. A):A31-A37.
82. Rabinowitz M., Zak R. Mitochondria and cardiac hypertrophy. Circ Res 1975, 36:367-376.
83. Gong G., Liu J., Liang P., Guo T., Hu Q., Ochiai K., et al. Oxidative capacity in failing hearts. Am J Physiol Heart Circ Physiol 2003, 285:H541-H548.
84. van Bilsen M., Smeets P.J., Gilde A.J., van der Vusse G.J. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome?. Cardiovasc Res 2004, 61:218-226.
85. Karamanlidis G., Nascimben L., Couper G.S., Shekar P.S., del Monte F., Tian R. Defective DNA replication impairs mitochondrial biogenesis in human failing hearts. Circ Res 2010, 106:1541-1548.
86. Bendall J.K., Cave A.C., Heymes C., Gall N., Shah A.M. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 2002, 105:293-296.
87. Cave A. Selective targeting of NADPH oxidase for cardiovascular protection. Curr Opin Pharmacol 2009, 9:208-213.
88. Kuroda J., Nakagawa K., Yamasaki T., Nakamura K., Takeya R., Kuribayashi F., et al. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells 2005, 10:1139-1151.
89. Grishko V., Pastukh V., Solodushko V., Gillespie M., Azuma J., Schaffer S. Apoptotic cascade initiated by angiotensin II in neonatal cardiomyocytes: role of DNA damage. Am J Physiol Heart Circ Physiol 2003, 285:H2364-H2372.
90. Nakamura K., Fushimi K., Kouchi H., Mihara K., Miyazaki M., Ohe T., et al. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998, 98:794-799.
91. Hirotani S., Otsu K., Nishida K., Higuchi Y., Morita T., Nakayama H., et al. Involvement of nuclear factor-kappa-B and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 2002, 105:509-515.
92. Byrne J.A., Grieve D.J., Bendall J.K., Li J.M., Gove C., Lambeth J.D., et al. Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin ii-induced cardiac hypertrophy. Circ Res 2003, 93:802-805.
93. Grieve D.J., Byrne J.A., Siva A., Layland J., Johar S., Cave A.C., et al. Involvement of the nicotinamide adenosine dinucleotide phosphate oxidase isoform Nox2 in cardiac contractile dysfunction occurring in response to pressure overload. J Am Coll Cardiol 2006, 47:817-826.
94. An S.J., Boyd R., Zhu M., Chapman A., Pimentel D.R., Wang H.D. NADPH oxidase mediates angiotensin II-induced endothelin-1 expression in vascular adventitial fibroblasts. Cardiovasc Res 2007, 75:702-709.
95. Johar S., Cave A.C., Narayanapanicker A., Grieve D.J., Shah A.M. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006, 20:1546-1548.
96. Cucoranu I., Clempus R., Dikalova A., Phelan P.J., Ariyan S., Dikalov S., et al. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 2005, 97:900-907.
97. Maejima Y., Kuroda J., Matsushima S., Ago T., Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol 2011, 50:408-416.
98. Molkentin J.D., Lu J.R., Antos C.L., Markham B., Richardson J., Robbins J., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998, 93:215-228.
99. Molkentin J.D., Kalvakolanu D.V., Markham B.E. Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene. Mol Cell Biochem 1994, 14:4947-4957.
100. Passier R., Zeng H., Frey N., Naya F.J., Nicol R.L., McKinsey T.A., et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000, 105:1395-1406.
101. Haberland M., Montgomery R.L., Olson E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009, 10:32-42.
102. Saha R.N., Pahan K. Hats and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ 2006, 13:539-550.
103. Hu E., Chen Z., Fredrickson T., Zhu Y., Kirkpatrick R., Zhang G.F., et al. Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 2000, 275:15254-15264.
104. Kook H., Lepore J.J., Gitler A.D., Lu M.M., Wing-Man Yung W., et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest 2003, 112:863-871.
105. Trivedi C.M., Luo Y., Yin Z., Zhang M., Zhu W., Wang T., et al. HDA2 regulates the cardiac hypertrophic response by modulating GSK3? activity. Nat Med 2007, 13:324-331.
106. Nott A., Watson P.M., Robinson J.D., Crepaldi L., Riccio A. S-nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 2008, 455:411-415.
107. McKinsey T.A., Zhang C.L., Olson E.N. Signaling chromatin to make muscle. Curr Opin Cell Biol 2002, 14:763-772.
108. Zhang C.L., McKinsey T.A., Chang S., Antos C.L., Hill J.A., Olson E.N. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110:479-488.
109. McKinsey T.A., Zhang C.L., Lu J., Olson E.N. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature 2000, 408:106-111.
110. Grozinger C.M., Schreiber S.L. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA 2000, 97:7835-7840.
111. Backs J., Olson E.N. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006, 98:15-24.
112. Kirsh O., Seeler J.S., Pichler A., Gast A., Muller S., Miska E., et al. The SUMO E3 ligase Ranbp2 promotes modification of the HDAC4 deacetylase. EMBO J 2002, 21:2682-2691.
113. Potthoff M.J., Wu H., Arnold M.A., Shelton J.M., Backs J., McAnally J., et al. Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers. J Clin Invest 2007, 117:2459-2467.
114. Shen X., Zheng S., Metreveli N.S., Epstein P.N. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55:798-805.
115. Nojiri H., Shimizu T., Funakoshi M., Yamaguchi O., Zhou H., Kawakami S., et al. Oxidative stress causes heart failure with impaired mitochondrial respiration. J Biol Chem 2006, 281:33789-33801.
116. Ren J., Li Q., Wu S., Li S.Y., Babcock S.A. Cardiac overexpression of antioxidant catalase attenuates aging-induced cardiomyocyte relaxation dysfunction. Mech Ageing Dev 2007, 128:276-285.
117. Wu S., Li Q., Du M., Li S.Y., Ren J. Cardiac-specific overexpression of catalase prolongs lifespan and attenuates ageing-induced cardiomyocyte contractile dysfunction and protein damage. Clin Exp Pharmacol Physiol 2007, 34:81-87.
118. Berndt C., Lillig C.H., Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 2007, 292:H1227-H1236.
119. Masutani H., Yodoi J. Thioredoxin. Overview. Methods Enzymol 2002, 347:279-286.
120. Yamamoto M., Yang G., Hong C., Liu J., Holle E., Yu X., et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003, 112:1395-1406.
121. Ago T., Sadoshima J. Thioredoxin and ventricular remodeling. J Mol Cell Cardiol 2006, 41:762-773.
122. Matsushima S, Zablocki D, Sadoshima J. Application of recombinant thioredoxin1 for treatment of heart disease. J Mol Cell Cardiol [e-Pub ahead of print October 16, 2010].
123. Rajasekaran N.S., Connell P., Christians E.S., Yan L.J., Taylor R.P., Orosz A., et al. Human alpha B-crystallin mutation causes oxido-reductive stress and protein aggregation cardiomyopathy in mice. Cell 2007, 130:427-439.
124. Trotter E.W., Grant C.M. Thioredoxins are required for protection against a reductive stress in the yeast Saccharomyces cerevisiae. Mol Microbiol 2002, 46:869-878.
125. Vicart P., Caron A., Guicheney P., Li Z., Prevost M.C., Faure A., et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet 1998, 20:92-95.
126. Wang X., Osinska H., Klevitsky R., Gerdes A.M., Nieman M., Lorenz J., et al. Expression of R120G-alphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ Res 2001, 89:84-91.
127. Zhang X., Min X., Li C., Benjamin I.J., Qian B., Ding Z., et al. Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27. Hypertension 2010, 55:1412-1417.
128. Bencsik P., Kupai K., Giricz Z., Gorbe A., Huliak I., Furst S., et al. Cardiac capsaicin-sensitive sensory nerves regulate myocardial relaxation via S-nitrosylation of SERCA: role of peroxynitrite. Br J Pharmacol 2008, 153:488-496.
129. Xu L., Eu J.P., Meissner G., Stamler J.S. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 1998, 279:234-237.
130. Maejima Y., Adachi S., Morikawa K., Ito H., Isobe M. Nitric oxide inhibits myocardial apoptosis by preventing caspase-3 activity via S-nitrosylation. J Mol Cell Cardiol 2005, 38:163-174.
131. Kohr M.J., Sun J., Aponte A., Wang G., Gucek M., Murphy E., et al. Simultaneous measurement of protein oxidation and S-nitrosylation during preconditioning and ischemia/reperfusion injury with resin-assisted capture. Circ Res 2011, 108:418-426.
132. Turko I.V., Murad F. Protein nitration in cardiovascular diseases. Pharmacol Rev 2002, 54:619-634.
133. Mihm M.J., Coyle C.M., Schanbacher B.L., Weinstein D.M., Bauer J.A. Peroxynitrite induced nitration and inactivation of myofibrillar creatine kinase in experimental heart failure. Cardiovasc Res 2001, 49:798-807.
134. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003, 140-141:105-112.
135. Guzik T.J., West N.E., Pillai R., Taggart D.P., Channon K.M. Nitric oxide modulates superoxide release and peroxynitrite formation in human blood vessels. Hypertension 2002, 39:1088-1094.
136. Levrand S., Vannay-Bouchiche C., Pesse B., Pacher P., Feihl F., Waeber B., et al. Peroxynitrite is a major trigger of cardiomyocyte apoptosis in vitro and in vivo. Free Radic Biol Med 2006, 41:886-895.
137. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van der Vliet A., Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001, 276:29596-29602.
138. Lalu M.M., Wang W., Schulz R. Peroxynitrite in myocardial ischemia-reperfusion injury. Heart Fail Rev 2002, 7:359-369.
139. Virag L., Szabo C. The therapeutic potential of poly(ADP-Ribose) polymerase inhibitors. Pharmacol Rev 2002, 54:375-429.